BET阻害とSMAC模倣剤を組み合わせると,腫瘍の成長を抑制し,臨床前がんモデルにおける免疫監視を誘発する
Ksenija Slavic Obradovic1, Florian Ebner1, Artem V Artemov1
1Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Cell reports. Medicine
|August 26, 2025
まとめ
SMAC模倣剤 (SMACm) とBET阻害剤 (BETi) の組み合わせは,がん治療において有望であることが示されています. この薬の組み合わせは,がん細胞の増殖を効果的に減らし,腫瘍の微小環境を標的として抗腫瘍免疫を強化します.
科学分野:
- 腫瘍学
- 分子生物学
- 免疫学
背景:
- 第二次ミトコンドリア活性化カスパース (SMAC) ミメティック (SMACm) とブロモドメインおよびエクストラターミナルドメイン (BET) 阻害剤 (BETi) は新しい抗がん療法薬である.
- モノセラピーでは限られた臨床効果が認められ,併用療法が必要となった.
研究 の 目的:
- SMACmアンタゴニスト (BI 891065) とBET阻害剤 (BI 894999) を併用してがん治療の有効性を評価する.
- この組み合わせが癌細胞増殖,細胞死経路,腫瘍微環境 (TME) に与える影響を調査する.
主な方法:
- 管腺癌 (PDAC) のシンジェニックモデルを使用した.
- 配列化 (CITE-seq) と高度なフローサイトメトリーによるトランスクリプトームとエピトープのセルラーインデックスを含むマルチオーム分析を使用した.
主要な成果:
- SMACmとBETiの組み合わせは,様々な組織における癌細胞の増殖を著しく阻害しました.
- 細胞死を促進する経路の調節を示している.
- 増強された抗腫瘍免疫と 免疫抑制性TMEの減少を示した.
結論:
- BET阻害剤とSMAC模倣剤の組み合わせは,がんに対する有望な治療戦略です.
- この組み合わせは,腫瘍細胞の内在的メカニズムとTME依存の抗腫瘍反応の両方に多層の影響を及ぼします.
関連する概念動画
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K


